A
Arvinas
Pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases
About Arvinas
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat debilitating and life-threatening diseases. The company operates in the biotechnology sector and primarily serves patients suffering from conditions caused by disease-causing proteins. Arvinas leverages its proprietary technology platform to create proteolysis targeting chimeras (PROTAC® protein degraders), which are designed to harness the body's natural protein disposal system to selectively degrade harmful proteins.
Read full description
The company's business model revolves around the discovery, development, and commercialization of these novel therapies. Arvinas generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, as well as through the potential commercialization of its own drug candidates.
Arvinas operates in the global biopharmaceutical market, targeting a range of diseases including cancer and neurodegenerative disorders. The company aims to improve patient outcomes by providing targeted, effective treatments that address the underlying causes of these diseases.
At a glance
- Founded
- 2013
- Headquarters
- New Haven, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Arvinas.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
5AM Ventures
Canaan
Connecticut Innovations- EVElm Street Ventures
RA Capital Management
New Leaf Venture Partners
OrbiMed
Series B and later5 investors entered at this stage
Nextech Invest- NVNextech Venture
Deerfield- SCSirona Capital
Hillhouse Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
115 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arvinas on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arvinas on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.